genosmart DX Prostate Cancer ^UrineRNA-8

Urine RNA testing to reveal and monitor prostate cancer status

Useful for

The DB-DNA-ProstateCancer-Urine8 Panel is a targeted resequencing assay for the screening and stratification of prostate cancer from urine. This is a liquid biopsy (urine) RNA-based assay.

Speciment type requirements

20 ml of urine mixed with specific preservative ask for more information

Required information

-

Clinical interpretation

The panel is intended to be used as a screening method and may give a more precise result than the usual PSA-based method. Targeted cancer therapies are defined as antibody or small molecule drugs that block the growth and spread of cancer by interfering with specific cell molecules involved in tumour growth and progression. Multiple targeted therapies have been approved for treatment of specific cancers. Molecular genetic profiling is often needed to identify targets amenable to targeted therapies and to minimize treatment costs and therapy-associated risks.

Cautions

This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk. A negative (wild-type) result does not rule out the presence of a mutation or rearrangement (fusion) that may be present but below the limits of detection of this assay. Rare polymorphisms may be present that could lead to false-negative or false-positive results. Test results should be interpreted in the context of clinical findings, tumour sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for updated interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.